Fibroblast growth factor receptor 1 and related ligands in small-cell lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 7, 2015, Pages 1083-1090

  Zhang, Liping ^a,b   Yu, Hui ^a,b   Badzio, Andrzej ^c   Boyle, Theresa A ^b   Schildhaus, Hans Ulrich ^d   Lu, Xian ^e   Dziadziuszko, Rafal ^c   Jassem, Jacek ^c   Varella Garcia, Marileila ^b   Heasley, Lynn E ^e   Kowalewski, Ashley A ^b   Ellison, Kim ^b   Chen, Gang ^a   Zhou, Caicun ^a   Hirsch, Fred R ^b  

^a TONGJI UNIVERSITY   (China)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Fibroblast growth factor 2; Fibroblast growth factor 9; Fibroblast growth factor receptor 1; Small cell lung cancer

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR 1; LIGAND; MESSENGER RNA; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; FGFR1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; SILVER IN SITU HYBRIDIZATION; SMALL CELL LUNG CANCER; TISSUE MICROARRAY; ADULT; AGED; BIOSYNTHESIS; COHORT ANALYSIS; ENZYMOLOGY; FEMALE; GENETICS; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

ADULT; AGED; COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIGANDS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA;

EID: 84942917739     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000562     Document Type: Article

References (39)

1. Govindan R, Page N, Morgensztern D, Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006 24 4539 4544
2. Giaccone G., Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005 23 3235 3242
3. Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 363 1693 1703
4. Beenken A, Mohammadi M., The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009 8 235 253
5. Behrens C, Lin HY, Lee JJ, Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 2008 14 6014 6022
6. Marek L, Ware KE, Fritzsche A, Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 2009 75 196 207
7. Brooks AN, Kilgour E, Smith PD., Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012 18 1855 1862
8. Weiss J, Sos ML, Seidel D, Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010 2 62ra93
9. Kim HR, Kim DJ, Kang DR, Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013 31 731 737
10. Tran TN, Selinger CI, Kohonen-Corish MR, Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer 2013 81 462 467
11. Wynes MW, Hinz TK, Gao D, FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res 2014 20 3299 3309
12. Peifer M, Fernández-Cuesta L, Sos ML, Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012 44 1104 1110
13. Pardo OE, Latigo J, Jeffery RE, The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 2009 69 8645 8651
14. Pardo OE, Wellbrock C, Khanzada UK, FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 2006 25 3078 3088
15. Hideki T, Kenzo S, Hiroyuki Y, Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Caner Res 2013 11 759 767
16. Zhang H, Lorianne M, Baker K, FP-1039 (FGFR1:Fc), a soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics October 22-26, 2007 San Francisco, CA. AACR, Abstract no. B55.
17. Badzio A, Wynes MW, Dziadziuszko R, Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. J Thorac Oncol 2010 5 1905 1911
18. Travis WD, Brambilla E, Muller-Hermelink HK, World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart 2004 Lyon IARC Press
19. Schultheis AM, Bos M, Schmitz K, Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Mod Pathol 2014 27 214 221
20. Wang F, Flanagan J, Su N, RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2012 14 22 29
21. Kohler LH, Mireskandari M, Knösel T, FGFR1 expression and gene copy numbers in human lung cancer. Virchows Arch 2012 461 49 57
22. Wolff AC, Hammond ME, Hicks DG, American Society of Clinical Oncology; College of American Pathologists Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013 31 3997 4013
23. Stachowiak MK, Macher PA, Stachowiak EK, Integrative nuclear signaling in cell development-A role for FGFR-1. DNA Cell Biol 2007 26 811 826
24. Yang F, Gao Y, Geng J, Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol 2013 6 2846 2854
25. Anish T, Jih-Hsiang L, Zied A, Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer. J Thorac Oncol 2014 9 567 571
26. Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Definition of a fluorescence in-situ hybridization score identifies high-And low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 2012 25 1473 1480
27. An NS, Yan J, Hee JL, FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer. Virchows Arch 2014 465 547 558
28. Pesch B, Kendzia B, Gustavsson P, Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 2012 131 1210 1219
29. Zhang J, Zhang L, Su X, Translating the therapeutic potential of AZD4547 in FGFR1-Amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res 2012 18 6658 6667
30. Wolf J, LoRusso PM, Camidge RD, A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors [Abstract]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research March 31 to April 4, 2012 Chicago, IL. AACR, Abstract no. LB-122.
31. Andre F, Ranson M, Dean E, Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors [Abstract]. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research April 6-10, 2013 Washington, DC. AACR, Abstract no. LB-145.
32. Rui W, Lei W, Yuan L, FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small-cell lung cancer. Clin Cancer Res 2014 20 4107 4114
33. Wu YM, Su F, Kalyana-Sundaram S, Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013 3 636 647
34. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003 21 3798 3807
35. Peled N, Palmer G, Hirsch FR, Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012 7 e14 e16
36. Sun JM, Choi YL, Won JK, A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 2012 7 e36 e38
37. Ren S, Hirsch FR, Varella-Garcia M, Atypical negative ALK break-Apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol 2014 9 e21 e23
38. Marina PZ, Hirsch FR, Lior SG, Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. The Oncologist 2015 20 1 7
39. Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM., Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009 4 578 585